ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.77
-1.09%
US Tech 100
20,778.00
-0.69%
S&P 500
6,040.53
-0.50%
US Dollar vs CAD
1.45405
0.00%
Bitcoin
102,135.05
-0.27%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE

  6. ADC Therapeutics SA (ADCT) Share Price

ADC Therapeutics SA

ADC Therapeutics SA (ADCT)

NYSE
1.68
-0.04
(-2.33%)
Closed February 01 3:00PM
Delayed by 15 minutes
1.67
-0.01
(-0.60%)
After Hours: 6:13PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
1.67
Bid
-
Ask
-
Volume
671,757
1.64 Day's Range 1.75
1.585 52 Week Range 6.04
Market Cap
161.472M
Previous Close
1.72
Open
1.70
Last Trade
50764
@
1.68
Last Trade Time
Financial Volume
US$ 1,133,729
VWAP
1.6877
Average Volume (3m)
980,738
Shares Outstanding
96,689,617
Dividend Yield
-
PE Ratio
-0.69
Earnings Per Share (EPS)
-2.43
Revenue
69.56M
Net Profit
-234.53M

About ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602,... ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212. Show more

Sector
Drugs And Proprietary-whsl
Industry
Drugs And Proprietary-whsl
Website
www.adctherapeutics.com
Headquarters
Lausanne, Che
Founded
-
ADC Therapeutics SA is listed in the Drugs And Proprietary-whsl sector of the New York Stock Exchange with ticker ADCT. The last closing price for ADC Therapeutics was US$1.72. Over the last year, ADC Therapeutics shares have traded in a share price range of US$ 1.585 to US$ 6.04.

ADC Therapeutics currently has 96,689,617 shares outstanding. The market capitalization of ADC Therapeutics is US$166.31 million. ADC Therapeutics has a price to earnings ratio (PE ratio) of -0.69.

Ask ADVFN Intelligence (AI)

ADCT Latest News

More News

ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference PR Newswire LAUSANNE, Switzerland, Jan. 30, 2025 LAUSANNE, Switzerland, Jan. 30, 2025 /PRNewswire/ -- ADC...

January 30 2025
PR Newswire (US)

Form 8-K - Current report

January 13 2025
Edgar (US Regulatory)

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan PR Newswire LAUSANNE, Switzerland, Jan. 2, 2025 LAUSANNE, Switzerland, Jan. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:...

January 02 2025
PR Newswire (US)

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma PR Newswire LAUSANNE...

December 30 2024
PR Newswire (US)

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell...

December 11 2024
PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities

December 09 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

December 09 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

December 09 2024
Edgar (US Regulatory)

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular...

December 09 2024
PR Newswire (US)

ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial

ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial PR Newswire LAUSANNE, Switzerland, Dec. 6, 2024 Company to host corporate update webcast to share results on December 11...

December 06 2024
PR Newswire (US)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.12-6.703910614531.791.8251.5855266761.7050394CS
4-0.31-15.65656565661.982.13991.5855620091.81086283CS
12-1.38-45.24590163933.053.491.5859807382.36381477CS
26-1.83-52.28571428573.53.5451.5856300812.57272603CS
52-1.62-49.24012158053.296.041.5856806883.31022799CS
156-13.32-88.85923949314.9917.890.3599085369793.50040697CS
260-28.33-94.43333333333056.58990.3599084309618.88846708CS

ADCT - Frequently Asked Questions (FAQ)

What is the current ADC Therapeutics share price?
The current share price of ADC Therapeutics is US$ 1.67
How many ADC Therapeutics shares are in issue?
ADC Therapeutics has 96,689,617 shares in issue
What is the market cap of ADC Therapeutics?
The market capitalisation of ADC Therapeutics is USD 166.31M
What is the 1 year trading range for ADC Therapeutics share price?
ADC Therapeutics has traded in the range of US$ 1.585 to US$ 6.04 during the past year
What is the PE ratio of ADC Therapeutics?
The price to earnings ratio of ADC Therapeutics is -0.69
What is the cash to sales ratio of ADC Therapeutics?
The cash to sales ratio of ADC Therapeutics is 2.34
What is the reporting currency for ADC Therapeutics?
ADC Therapeutics reports financial results in USD
What is the latest annual turnover for ADC Therapeutics?
The latest annual turnover of ADC Therapeutics is USD 69.56M
What is the latest annual profit for ADC Therapeutics?
The latest annual profit of ADC Therapeutics is USD -234.53M
What is the registered address of ADC Therapeutics?
The registered address for ADC Therapeutics is ROUTE DE LA CORNICHE 3B, LAUSANNE, 1066
What is the ADC Therapeutics website address?
The website address for ADC Therapeutics is www.adctherapeutics.com
Which industry sector does ADC Therapeutics operate in?
ADC Therapeutics operates in the DRUGS AND PROPRIETARY-WHSL sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MBIMBIA Inc
US$ 7.11
(15.42%)
2.37M
ALURAllurion Technologies Inc
US$ 6.07
(13.46%)
571.74k
SESSES AI Corporation
US$ 1.19
(13.33%)
24.78M
ENFYEnlightify Inc
US$ 1.36
(12.40%)
95.69k
LITBLightInTheBox Holding Co Ltd
US$ 1.155
(12.14%)
17.51k
DECKDeckers Outdoor
US$ 177.46
(-20.46%)
15.04M
BZHBeazer Homes USA Inc New
US$ 22.18
(-19.93%)
2.11M
VSTSVestis Corporation
US$ 14.00
(-11.62%)
6.16M
KOREKORE Group Holdings Inc
US$ 2.29
(-9.13%)
36.39k
NOVASunnova Energy International Inc
US$ 2.565
(-9.04%)
14.63M
FFord Motor Company
US$ 10.08
(-0.79%)
103.95M
QBTSD Wave Quantum Inc
US$ 5.94
(5.32%)
74.97M
BBDBanco Bradesco SA
US$ 2.12
(0.47%)
55.74M
NUNu Holdings Ltd
US$ 13.25
(-1.41%)
47.85M
VZVerizon Communications Inc
US$ 39.39
(-0.20%)
44.69M

ADCT Discussion

View Posts
Jab44 Jab44 2 months ago
Now under $2
👍️0
Jab44 Jab44 2 months ago
I guess regardless of how Ron Square and company are excited by the strong results of Lotis the street gives it a thumbs down.
👍️0
glenn1919 glenn1919 2 months ago
ADCT...................................https://stockcharts.com/h-sc/ui?s=ADCT&p=W&b=5&g=0&id=p86431144783
👍️0
Jab44 Jab44 2 months ago
Nice move this morning . Hopefully good news with Lotis-7 clinical trial.
👍️0
Jab44 Jab44 2 months ago
This stock is an utter mess. Good news is needed soon or it will be under $1.50
👍️0
Monksdream Monksdream 5 months ago
ADCT under $3
👍️0
glenn1919 glenn1919 7 months ago
ADCT....................................https://stockcharts.com/h-sc/ui?s=ADCT&p=W&b=5&g=0&id=p86431144783
👍️0
PonkenPlonken PonkenPlonken 7 months ago
Somethings very right here. Looking for 5+
👍️0
glenn1919 glenn1919 7 months ago
ADCT......................................https://stockcharts.com/h-sc/ui?s=ADCT&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 11 months ago
ADCT...MONSTER
👍️0
TrendTrade2016 TrendTrade2016 11 months ago
ADCT MASSIVE BREAK OUT HERE
👍️0
glenn1919 glenn1919 12 months ago
ADCT..................................https://stockcharts.com/h-sc/ui?s=ADCT&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 12 months ago
ADCT new 52 week high
👍️0
Monksdream Monksdream 12 months ago
ADCT new 52 week high
👍️0
TrendTrade2016 TrendTrade2016 12 months ago
Brilliantly played to 4.80. Precision technical charting.
👍️0
TrendTrade2016 TrendTrade2016 12 months ago
ADCT...TARGET COMING IN
👍️0
glenn1919 glenn1919 12 months ago
ADCT......................................................https://stockcharts.com/h-sc/ui?s=ADCT&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 12 months ago
ADCT monster
👍️0
TrendTrade2016 TrendTrade2016 12 months ago
ADCT...4.82 NEXT
👍️0
TrendTrade2016 TrendTrade2016 12 months ago
ADCT..WAITED TOO LOG TO ENTER THIS BEAST!!!!
👍️0
glenn1919 glenn1919 12 months ago
ADCT.......................................https://stockcharts.com/h-sc/ui?s=ADCT&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 1 year ago
ADCT.................................................................https://stockcharts.com/h-sc/ui?s=ADCT&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 1 year ago
ADCT.........................................https://stockcharts.com/h-sc/ui?s=ADCT&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 1 year ago
ADCT...........................................https://stockcharts.com/h-sc/ui?s=ADCT&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 1 year ago
ADCT......................................https://stockcharts.com/h-sc/ui?s=ADCT&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 1 year ago
ADCT.........................................https://stockcharts.com/h-sc/ui?s=ADCT&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 1 year ago
ADCT.....................................https://stockcharts.com/h-sc/ui?s=ADCT&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 1 year ago
ADCT new 52 week low
👍️0
glenn1919 glenn1919 1 year ago
ADCT.......................https://stockcharts.com/h-sc/ui?s=ADCT&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 1 year ago
ADCT new 52 week low
👍️0
Monksdream Monksdream 1 year ago
ADCT new 52 week low
👍️0
Monksdream Monksdream 1 year ago
ADCT new 52 week low
👍️0
Monksdream Monksdream 1 year ago
ADCT new 52 week low
👍️0
Monksdream Monksdream 1 year ago
ADCT new 52 week low
👍️0
Monksdream Monksdream 1 year ago
ADCT new 52 week low

👍️0
Monksdream Monksdream 2 years ago
ADTC new 52 week low
👍️0
tw0122 tw0122 2 years ago
ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL
👍️0
81vette 81vette 2 years ago
Ripe for merger/buyout/Big Bang boom
👍️0
81vette 81vette 2 years ago
Revenue increased yoy,profits increase yoy,tons of cash on hand,the more I dig the more I confident I am, (usually more digging,less liking)
👍️0
81vette 81vette 2 years ago
$3.3m print and $760k omg,FOLLOW THE $ is the saying
👍️0
81vette 81vette 2 years ago
Great company,I loaded 2tons today lots of institutional buying and insiders have lots of skin in it,28 patents pending for awhile,many should be getting approved soon.macd crossed to bulls on March 27th,I am following the $,3 times it crossed in last year period,every time a run continued for many days,low risk high reward babe
👍️ 1
conix conix 2 years ago
ADCT in Seeking Alpha

https://seekingalpha.com/article/4561171-adc-therapeutics-running-through-bad-luck?
👍️0
north40000 north40000 3 years ago
https://ih.advfn.com/stock-market/NYSE/adc-therapeutics-ADCT/stock-news/87749724/adc-therapeutics-obtient-un-code-j-permanent-pour
👍️0
ibelurkin ibelurkin 4 years ago
FDA approves ADC's biologic Zynlonta for B-cell lymphom

👍️0
stockguard stockguard 4 years ago
ADC Therapeutics SA
Cowen healthcare conference: March 4th, 2021

https://wsw.com/webcast/cowen81/adct/1925484
👍️0
~WAVE~ ~WAVE~ 15 years ago
Great News! A Buyout!
The Stock Compound Called It!
👍️0
~WAVE~ ~WAVE~ 15 years ago
ADCT got called this morning on The Stock Compound's scan.
stockcompound.blogspot.com/

That pays for my membership fee!
👍️0
zomniac zomniac 15 years ago
Whoaaa
What's happening ???
👍️0
mlkrborn mlkrborn 15 years ago
DC Telecommunications (ADCT Quote) rallied by 80 cents, or 14.9%, to $6.18 after the broadband communications provider said late Monday it had a fiscal first-quarter profit of 2 cents, better than analysts' expectations that ADC would break even in the quarter. ADC also offered in-line earnings and revenue guidance for its fiscal second quarter. Volume topped 5.71 million shares, compared to the 50-day average daily volume of 2.07 million, according to the Nasdaq.
👍️0
OldAIMGuy OldAIMGuy 17 years ago
Nice uptick in ADCT today. Earnings and sales are up on the most recent report.

Best regards, Tom
👍️0

Your Recent History

NYSE
ADCT
ADC Therapeutics
TG
NVV1
Novavax
BIT
UV8C8T
UniCredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads